Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholesterol test launch

This article was originally published in The Tan Sheet

Executive Summary

Predictive medicine technology developer International Medical Innovations (IMI) will introduce its PREVU Point of Care cholesterol test for the physician, clinic and pharmacist in the first quarter of 2005. The UK switch of statin Zocor to nonprescription status "shows that point-of-care counseling by healthcare professionals is a key focus in combating heart disease," IMI says. "We expect this environment to create important opportunities for PREVU Skin Sterol Test as a new tool for risk assessment." McNeil Consumer Healthcare markets the product worldwide (1"The Tan Sheet" June 7, 2004, p. 10). The consumer version of PREVU will enter clinical trials in the first half of 2005...
Advertisement

Related Content

McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI

Topics

Advertisement
UsernamePublicRestriction

Register

PS097612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel